Diabetes mellitus (DM) affects more than 29 million individuals in the USA alone 1. The predilection of diabetes to cause premature complications and mortality from cardiovascular disease (CVD) has long been appreciated, with CVD death rates ∼1.7 times higher in adults diagnosed with DM 1,2. Lifestyle modifications and conventional medications are the mainstay of treatment in diabetic patients with or at risk for CVD. Natural approaches to CVD risk reduction, including diet, exercise, and herbal supplements, have demonstrated promising results in diabetic patients (Table 1). Herein, we provide an overview of conventional treatments and review the literature supporting natural approaches to CVD risk reduction in DM. We focus on natural and herbal supplements which have shown promise in treating DM alone or the CVD complications of DM.
Complications of diabetes mellitus
DM is well-recognized as a potent risk factor for vascular injury, owing in part to its effect on oxidative stress 3,4. Hyperglycemia-induced overproduction of superoxide dismutase by the mitochondrial electron-transport chain activates downstream deleterious pathways and results in production of free radicals, which leads to oxidative stress and systemic inflammation 5–8. Persistent hyperglycemia also causes the formation of advanced glycation end products through nonenzymatic glycation, which further contributes to oxidative stress production 9,10. The markers of oxidative stress most commonly associated with DM include superoxide dismutase, nitrogen dioxide, and peroxynitrite 11,12. Oxidative stress and advanced glycation end products combine to activate the protein kinase C pathway 13. Activation of protein kinase C is linked to cardiomyopathy, atherosclerosis, diabetic retinopathy, and diabetic nephropathy 13. The polyol and hexosamine pathways are also associated with elevated levels of oxidative stress and contribute to vascular complications of DM 6. Inflammatory biomarkers, such as high-sensitivity C-reactive protein and fibrinogen, reflect oxidative stress and have been shown to prospectively predict the risk of adverse cardiac events 14.
The accumulation of vascular injury over time leads to the microvascular and macrovascular complications seen in DM. Microvascular complications include retinopathy, macular edema, neuropathy, and nephropathy 1. The macrovascular complications of coronary artery disease, peripheral vascular disease, and cerebrovascular disease contribute to most mortality in DM 15. Individuals with DM, once adjusted for population age differences, have a relative risk of 1.7 for cardiovascular death and 1.8 for hospitalization for myocardial infarction (MI), and are 1.5 times more likely to experience a stroke 1. After acute MI, patients with DM have an 18-month mortality of 36.4% compared with 25.7% in the nondiabetic population 16. In addition, many of the metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD), including hypertension, dyslipidemia, and increased visceral adipose tissue, are comorbid in individuals with DM 17,18.
Guidelines for the treatment of diabetes mellitus
The ADA and American Heart Association (AHA) have issued a combined scientific statement for prevention of CVD in DM 19. The cornerstone of current recommendations is therapeutic lifestyle management, including regular physical activity (PA), improved nutrition, and weight loss. Blood pressure targets of less than 140/90 mmHg should be achieved in all patients with DM; lower targets (i.e. <130 mmHg systolic) may be appropriate in select populations 19.
The current recommendation for blood glucose control is to treat to a glycated hemoglobin (HbA1c) of 7.0% primarily to reduce microvascular complications 20. Despite an established association between hyperglycemia and CVD, intensive lowering of HbA1c has not been clearly shown to decrease the macrovascular complications of DM 21.
Conventional pharmacotherapy for diabetes mellitus
Since 1980, the prevalence of diabetes has remained stable or increased in all countries tracking these data 22. Included in the first line of defense against vascular disease in DM patients is the control of blood glucose. For patients with type 2 DM, metformin remains the cornerstone of oral hypoglycemic therapy through its augmentation of hepatic insulin sensitivity. Dipeptidyl peptidase-4 inhibitors improve functioning of the pancreatic islet cells by preventing degradation of incretin hormones 23. Insulin, in both its long-acting and short-acting forms, is utilized after failure of oral hypoglycemic therapy or in cases of severely uncontrolled DM. In addition to blood glucose management, several other medications are important for reducing CVD risk (Fig. 1).
Aspirin is the foundation for antiplatelet therapy, used for the primary and secondary prevention of coronary and cerebrovascular events. By acetylating cyclooxygenase-1’s serine residue 529 in prehepatic circulation, aspirin prevents arachidonic acid from accessing and activating the cyclooxygenase-1 enzyme, which would otherwise activate thromboxane A2-induced platelet aggregation 24,25. Dosing of aspirin remains a topic of discussion. There has been no demonstrated additional benefit of high-dose (300–325 mg) as opposed to low-dose (75–100 mg) aspirin in the setting of MI, stroke, or overall cardiovascular mortality 26. The ADA recommends primary prevention with aspirin intake of 75–162 mg for diabetic individuals with a 10-year ASCVD risk more than 10% who are not at increased risk for bleeding, whereas aspirin is not recommended if the 10-year ASCVD risk is less than 5% 27. For 10-year ASCVD risk between 5 and 10%, the ADA recommends clinical judgment for aspirin initiation 27.
Statin therapy remains another cornerstone of therapy in the prevention of CVD in diabetics. These medications function through inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase. Statins have been associated with a statistically significant risk of new-onset diabetes 28–30. Practitioners are asked to remain mindful of risk factors for diabetes when placing their patients on statins 31. This risk is never meant to preclude treatment or provide contraindication to the initiation of statin therapy in a patient at significant risk for CVD. The ADA, with slight variants to the aforementioned criteria, cites trials demonstrating evidence of both primary 32,33 and secondary 34 prevention of CVD with statin therapy 35. The ADA guidelines for statin use in the diabetic population are based on age and the presence of ASCVD or ASCVD risk factors 27. All patients with established ASCVD, regardless of age, should be considered for treatment with a high-intensity statin 27.
Natural approaches for cardiovascular disease risk reduction in diabetes
The ADA published nutritional therapy recommendations for diabetic patients focusing on achieving glycemic control, as well as reducing CVD risk factors such as hypertension and dyslipidemia. The ADA recognized the challenges of creating a ‘one-size-fits-all’ dietary approach, as there is no ideal mix of macronutrients proven to meet the needs of all patients. Overall, the guidelines are intentionally broad to promote individualized nutritional therapy. The ADA recommends consuming minimally processed, nutrient-dense foods in appropriate portions. Carbohydrates – for example, should be derived from mostly vegetables, fruits, whole grains, and legumes. Dietary patterns should also include more foods containing omega-3 fatty acids, such as fatty fish, which favorably affects lipoproteins and may prevent heart disease 36–38.
The AHA, in collaboration with the ADA, issued a 2015 Scientific Statement with nutritional guidelines for CVD risk reduction in diabetics. Dietary patterns such as DASH (Dietary Approaches to Stop Hypertension) and Mediterranean, which emphasize intake of fruits, vegetables, and low-fat dairy, have been shown to lower CVD risk factors 19. The DASH diet can reduce low-density lipoprotein cholesterol by an average of 17.2 mg/dl, increase high-density lipoprotein (HDL) cholesterol by 4.3 mg/dl, and lower systolic and diastolic blood pressure by 13.6 and 9.5 mmHg, respectively 39. The Mediterranean diet may also raise HDL and decrease triglyceride levels, but more importantly, was shown to lower the incidence of CVD by 30% in diabetic patients 40,41.
Other AHA/ADA recommendations include limiting alcohol consumption to moderate intake and substituting healthy fats (monounsaturated and polyunsaturated fatty acids) for saturated and trans fats 19. The AHA uniquely recommends limiting sodium to less than 1500 mg/day, which differs from the ADA limit of 2300 mg/day 42. Reducing caloric intake is also recommended for overweight patients to improve CVD risk factors; however, weight loss was not shown to reduce the incidence of cardiovascular events in a large 10-year trial 43.
Reduction in CVD incidence, death from CVD, and all-cause mortality is believed to be attainable in the diabetic population with regular PA 44,45. A 2013 meta-analysis of 17 observational cohort studies involving diabetic patients supported the existence of an inverse, dose-dependent relationship of all-cause mortality and CVD risk with increased PA 46. The highest levels of PA were associated with a 40% reduction in all-cause mortality and 29% reduction in CVD, but any amount of PA resulted in risk reduction when compared with sedentary lifestyles 46. Similarly, a meta-analysis by Sluik et al. 47 found that higher levels of walking, leisure-time PA, and total PA resulted in lower CVD and total mortality in patients with type 2 DM. The study deviated from most others in the presence of a slight J-shaped association between PA and mortality as opposed to the more frequently reported linear association, which warrants further investigation 47. Although these data are promising and encourage the implementation of PA to affect cardiovascular complications in DM, randomized control trials (RCTs) supporting these results are needed as most of the existing evidence is from observational, cohort studies. Studies incorporating objective methods of assessing PA, as opposed to self-reporting by patients, would also be beneficial. Objective measures for exercise were used in a 2016 study by Lamb et al. 48 involving 308 recently diagnosed diabetic patients (mean age: 61 years, 66% male), and the study found that increasing exercise energy expenditure over 4 years resulted in greater reduction of clustered cardiometabolic risk, a precursor to CVD. In fact, a physically active lifestyle may eliminate the additional CVD risk in diabetic individuals relative to the nondiabetic population 49–51.
The spectrum of PA includes various forms of exercise, such as aerobic exercise (AE) and resistance training (RT). The type of exercise undertaken by a diabetic individual may affect health outcomes. Church et al. 52 randomized sedentary patients with DM to either an AE only group, a RT only group, a combined AE and RT group, or a nonexercising control group. The study found that only the combined group experienced a significant reduction in HbA1c after completion of the 9-month exercise program 52. The Diabetic Aerobic and Resistance Exercise trial found similar improvement in glycemic control with combined exercise as opposed to each exercise type alone after a 6-month exercise program 53.
A recent interest in the effects of high-intensity interval training (HIIT) on cardiovascular risk reduction has developed. HIIT involves very short spurts of high-intensity exercise intermingled with brief recovery periods. A randomized pilot study by Hollekim-Strand et al. 54 showed that HIIT was more effective than moderate intensity exercise in improving mean peak oxygen consumption, systolic function, and diastolic function in patients with DM. Cassidy et al. 55 found similar results with a 12-week HIIT program, noting improvement in cardiac structure in DM, namely left ventricular wall mass and systolic and diastolic function, which suggests that exercise intensity can improve diabetic cardiac dysfunction and lower cardiometabolic risk. Further research is needed to assess the long-term benefits of HIIT in relation to CVD-related complications.
Recommendations from leading health organizations emphasize the incorporation of exercise as routine health behavior for diabetic patients. The American College of Sports Medicine and the ADA released a joint position statement in 2010 asserting the decreased risk of all-cause and CV mortality provided by greater PA and fitness (American College of Sports Medicine evidence category C), recommending that people with diabetes engage in at least 150 min/week of moderate to vigorous AE without more than 2 consecutive days between aerobic sessions; moderate to vigorous RT 2–3 days/weekly should ideally be incorporated into the routine 56. The AHA released similar guidelines in 2009, recommending 150 min/week of moderate intensity AE (class I, level of evidence A) or 90 min/week of vigorous intensity AE (class I, level of evidence A), in addition to encouraging RT 3 days/week (class I, level of evidence A) 57.
Quercetin, a flavonoid found in many common dietary sources, including onions, kale, broccoli, grapes, and blueberries, has been shown to improve hyperglycemia in animal and human studies 58–60. In addition to its hypoglycemic effects, quercetin may provide further benefits to patients with DM by reducing comorbid CVD risk factors.
A study of obese rats with DM evaluated the effects of high-dose (10 mg/kg/day) and low-dose (2 mg/kg/day) quercetin supplementation on parameters of metabolic syndrome after 10 weeks 61. Despite similar initial body weights and food intake throughout the study, rats receiving high-dose quercetin had a lower body weight at the end of the study compared with obese controls (504.8 vs. 535.1 g, respectively, P<0.05) 61. Lean rats receiving high-dose quercetin also experienced a reduction in final body weight compared with their lean control counterparts (411.0 vs. 437.0 g, respectively, P<0.05) 61. Low-dose quercetin was not associated with decreased final body weight in either the lean or obese rats 61. However, the obese group receiving low-dose quercetin supplementation had significantly reduced total cholesterol (17.7%), triglycerides (29.5%), and free fatty acids (21.2%) compared with the obese controls (P<0.05 for all parameters) 61. The effects were mirrored in the obese, high-dose quercetin group (17.6, 33.3, and 24.6% reduction respectively, P<0.05 for all parameters) 61. There was no difference in the improvements between high-dose and low-dose groups 61. High-dose quercetin was also shown to decrease triglycerides (24%, P<0.01) and total cholesterol (18%, P<0.05), while increasing HDL cholesterol (15%, P<0.05), in mouse models of DM 59. The effects of quercetin are multifactorial and likely driven primarily by antioxidant properties and modulation of peroxisome proliferator-activated receptor-α 59.
Quercetin must be used with caution owing to its inhibition of the cytochrome P450 system. In particular, its use in conjunction with tamsulosin may potentiate vasodilation and orthostatic symptoms 62. Animal studies provide promising evidence that quercetin improves CVD risk factors; however, further human studies are required to prove its efficacy and safety.
Resveratrol is a polyphenol found in several fruits and nuts that has demonstrated potential beneficial effects in DM and the prevention of CVD 63. Interest in resveratrol supplementation has increased owing to its hyperglycemia-attenuating properties in animal models of DM 64,65. Results of early human studies are promising but conflicting in their effect on parameters of blood glucose and insulin resistance 66–70.
An RCT evaluating the effect of adjunctive resveratrol supplementation in DM for 3 months, in addition to standard oral hypoglycemic therapy, found an improvement in HbA1c, as well as reductions in total cholesterol (−14.32 vs. +6.90, P<0.0001), and systolic blood pressure (−11.78 vs. +7.76 mmHg, P<0.0001) in the resveratrol group compared with the group receiving oral hypoglycemic therapy alone, respectively 68. A similar, single-center RCT of 70 patients with DM demonstrated reduced systolic blood pressure and increased HDL cholesterol in patients receiving resveratrol supplementation 71. Unfortunately, other clinical studies have been less encouraging. A meta-analysis of seven studies found no change in lipid profiles with resveratrol 72. Further investigation into the efficacy of resveratrol, especially with respect to diabetic patients, is needed.
Resveratrol may exert its CVD-risk-reducing effects through antioxidant and anti-inflammatory properties. In a triple-blinded, RCT evaluating the effect of resveratrol in primary prevention of CVD (43% with DM), the group receiving resveratrol had significantly reduced markers of inflammation, including high-sensitivity C-reactive protein, after 1 year 63. Adverse effects of resveratrol supplementation have been rarely reported and include fever and cytopenia 73.
Bitter melon (Momordica charantia) is a shrub native to Asia, Africa, and Australia that has been used in these regions as a folk medicine for many years. More recently, bitter melon has been studied as a treatment for DM, hypertension, and hyperlipidemia 74,75.
The protective effects of bitter melon on CVD risk factors have been noted in animal models. For example, bitter melon extract given to diabetic rats significantly lowered systolic blood pressure compared with control, but did not affect diastolic blood pressure. There was also a trend toward lower cholesterol and triacylglycerol in the rats given bitter melon, but the association did not reach statistical significance 76. Human studies are sparse but have demonstrated similar findings. In one human RCT, diabetic patients receiving 4 g/day of bitter melon had a significant reduction in systolic blood pressure and triglycerides compared with baseline 77.
The antidiabetic and lipid-lowering effects of bitter melon are thought to act through several mechanisms. Extracts of bitter melon were shown to increase glucose consumption in the liver and decrease gluconeogenesis by enhancing insulin secretion and inhibiting fructose-1,6-bisphosphatase and glucose-6-phosphatase activity 78,79. It may also lower cholesterol by increasing fecal excretion of neutral steroids 75. The blood pressure-lowering effects of bitter melon are less understood, but may be mediated through adrenergic pathways 80.
Panax ginseng (PG), also called Asian or Korean ginseng, is a perennial herb native to Korea and China. The name Panax is derived from the Greek words pan (all) and akos (healing), which is a testament to its popularity in Asian medicine to treat illness and promote longevity. More recently, it has been identified as an alternative therapy for diabetes, hypercholesterolemia, and hypertension 81–84.
In an RCT of 19 patients with DM, PG supplementation as an adjunct to usual therapy demonstrated a 34% decrease in fasting plasma insulin 85. In contrast, a systematic review of four human trials found no antidiabetic effects of PG 86. The data are even less conclusive for the benefits of PG in lipid and blood pressure control. In one systematic review, five of nine studies on lipid control showed some improvement in one or more lipid parameters, including total cholesterol, triglycerides, and HDL. However, the trials were limited by size and design 87. In another meta-analysis of 17 trials, there was no effect on blood pressure with PG use, but a trend toward improvement in systolic blood pressure in diabetic patients was noted 88.
The medicinal properties of PG are thought to be mediated by AMP-activated protein kinase. In mouse models, ginsenosides, the pharmacologically active component of PG, were shown to lower blood glucose and triglyceride levels and protect against hepatic steatosis 83,84,89. However, human studies have shown mixed results with limited support of PG use for cardiovascular risk reduction. Larger, more standardized studies are still needed.
Oxidative stress, through previously described mechanisms, is a potential target for therapy owing to its association with vascular disease and endothelial dysfunction. Two such antioxidants that are commonly available as supplements are vitamin C (ascorbic acid) and vitamin E (α-tocopherol). Observational studies have indicated potential benefit with increased antioxidant intake 90. However, intervention trials to date have yielded mixed results 91. Endothelial function, as measured by flow-mediated dilation, was shown to improve with vitamins C and E supplementation in a small, uncontrolled trial, though there was no improvement in postischemic forearm hyperemia, another validated measurement of endothelial function and vascular stiffness 92. In a larger, randomized placebo-controlled trial, there was no improvement seen in flow-mediated dilation with the combination of vitamins C and E 93. Vitamins C and E individually have also shown similar mixed results 94,95. In addition, high-dose vitamin E supplementation may increase all-cause mortality 96. To date, the safety and efficacy of vitamins C and E supplementation remains to be established and should be avoided in the general population.
Diabetic patients are at substantially increased risk for CVD complications compared with their nondiabetic counterparts. In addition to therapy with conventional medications, several natural approaches have demonstrated efficacy in reducing CVD in DM. Lifestyle modification, which encompasses diet and PA, remains the mainstay of therapy. Several natural products have demonstrated potential favorable effects in DM, but no RCTs have shown definitive outcome benefits for reducing CVD events. Additional high-quality research is required to better characterize the beneficial and adverse effects of these supplements.
Dr Sandesara is supported by the Abraham J. and Phyllis Katz Foundation (Atlanta, GA, USA).
Conflicts of interest
There are no conflicts of interest.
1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229–234.
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615–1625.
4. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19:257–267.
5. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97:12222–12226.
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058–1070.
7. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94:3171–3182.
8. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23:599–622.
9. Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012; 1820:663–671.
10. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251:87–101.
11. Aouacheri O, Saka S, Krim M, Messaadia A, Maidi I. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes 2015; 39:44–49.
12. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4:5.
13. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106:1319–1331.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499–511.
15. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008; 45:1–16.
16. Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007; 28:540–545.
17. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14–S21.
18. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S54–S64.
19. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015; 132:691–718.
20. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37:9–16.
21. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d4169.
22. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387:1513–1530.
23. Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab 2014; 16:111–117.
24. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 2016; 374:728–737.
25. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
26. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233–1243.
27. American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care 2016; 39:S1–106.
28. Rha SW, Choi BG, Seo HS, Park SH, Park JY, Chen KY, et al. Impact of statin use on development of new-onset diabetes mellitus in Asian population. Am J Cardiol 2016; 117:382–387.
29. Maki KC, Dicklin MR, Baum SJ. Statins and diabetes. Endocrinol Metab Clin North Am 2016; 45:87–100.
30. Betteridge DJ, Carmena R. The diabetogenic action of statins – mechanisms and clinical implications. Nat Rev Endocrinol 2016; 12:99–110.
31. Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med 2015; 3:2050312115605518.
32. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29:1478–1485.
33. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53:298–304.
34. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29:1220–1226.
35. Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care 2009; 32 (Suppl 2): S384–S391.
36. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2014; 37 (Suppl 1): S120–S143.
37. American Diabetes Association. Standards of medical care in diabetes –2014. Diabetes Care 2014; 37 (Suppl 1): S14–S80.
38. Wu PY, Huang CL, Lei WS, Yang SH. Alternative health eating index and the Dietary Guidelines from American Diabetes Association both may reduce the risk of cardiovascular disease in type 2 diabetes patients. J Hum Nutr Diet 2016; 29:363–373.
39. Azadbakht L, Fard NR, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care 2011; 34:55–57.
40. Esposito K, Maiorino MI, Ciotola M, di Palo C, Scognamiglio P, Gicchino M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009; 151:306–314.
41. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368:1279–1290.
42. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation 2011; 123:1138–1143.
43. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145–154.
44. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107:2435–2439.
45. Batty GD, Shipley MJ, Marmot M, Smith GD. Physical activity and cause-specific mortality in men with type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. Diabet Med 2002; 19:580–588.
46. Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 2013; 36:471–479.
47. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med 2012; 172:1285–1295.
48. Lamb MJ, Westgate K, Brage S, Ekelund U, Long GH, Griffin SJ, et al. Prospective associations between sedentary time, physical activity, fitness and cardiometabolic risk factors in people with type 2 diabetes. Diabetologia 2016; 59:110–120.
49. Moe B, Eilertsen E, Nilsen TI. The combined effect of leisure-time physical activity and diabetes on cardiovascular mortality: the Nord-Trondelag Health (HUNT) cohort study, Norway. Diabetes Care 2013; 36:690–695.
50. Schreuder TH, Maessen MF, Tack CJ, Thijssen DH, Hopman MT. Life-long physical activity restores metabolic and cardiovascular function in type 2 diabetes. Eur J Appl Physiol 2014; 114:619–627.
51. Brown RE, Riddell MC, Macpherson AK, Canning KL, Kuk JL. All-cause and cardiovascular mortality risk in U.S. adults with and without type 2 diabetes: Influence of physical activity, pharmacological treatment and glycemic control. J Diabetes Complications 2014; 28:311–315.
52. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 2010; 304:2253–2262.
53. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147:357–369.
54. Hollekim-Strand SM, Bjorgaas MR, Albrektsen G, Tjonna AE, Wisloff U, Ingul CB. High-intensity interval exercise effectively improves cardiac function in patients with type 2 diabetes mellitus and diastolic dysfunction: a randomized controlled trial. J Am Coll Cardiol 2014; 64:1758–1760.
55. Cassidy S, Thoma C, Hallsworth K, Parikh J, Hollingsworth KG, Taylor R, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2016; 59:56–66.
56. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33:e147–e167.
57. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119:3244–3262.
58. Kim JH, Kang MJ, Choi HN, Jeong SM, Lee YM, Kim JI. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 2011; 5:107–111.
59. Jeong SM, Kang MJ, Choi HN, Kim JH, Kim JI. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr Res Pract 2012; 6:201–207.
60. Eldin IMT, Ahmed EM, HM AE. Preliminary study of the clinical hypoglycemic effects of Allium cepa
(red onion) in type 1 and type 2 diabetic patients. Environ Health Insights 2010; 4:71.
61. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008; 16:2081–2087.
62. Vrolijk MF, Haenen GR, Opperhuizen A, Jansen EH, Schiffers PM, Bast A. The supplement-drug interaction of quercetin with tamsulosin on vasorelaxation. Eur J Pharmacol 2015; 746:132–137.
63. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012; 110:356–363.
64. Gencoglu H, Tuzcu M, Hayirli A, Sahin K. Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters. Int J Food Sci Nutr 2015; 66:314–320.
65. Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exerc Metab 2014; 24:2–13.
66. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus – systematic review and meta-analysis. Mol Nutr Food Res 2015; 59:147–159.
67. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012; 67:1307–1312.
68. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012; 32:537–541.
69. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62:1186–1195.
70. Bashmakov YK, Assaad-Khalil SH, Abou Seif M, Udumyan R, Megallaa M, Rohoma KH, et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol 2014; 2014:816307.
71. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013; 2013:851267.
72. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2013; 71:822–835.
73. Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016; 51:456–464.
74. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to Momordica charantia
(karela). Br Med J (Clin Res Ed) 1981; 282:1823–1824.
75. Senanayake GV, Fukuda N, Nshizono S, Wang YM, Nagao K, Yanagita T, et al. Mechanisms underlying decreased hepatic triacylglycerol and cholesterol by dietary bitter melon extract in the rat. Lipids 2012; 47:495–503.
76. Clouatre DL, Rao SN, Preuss HG. Bitter melon extracts in diabetic and normal rats favorably influence blood glucose and blood pressure regulation. J Med Food 2011; 14:1496–1504.
77. Rahman IU, Khan RU, Rahman KU, Bashir M. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J 2015; 14:13.
78. Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia
with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull 2006; 29:1126–1131.
79. Sarkar S, Pranava M, Marita R. Demonstration of the hypoglycemic action of Momordica charantia
in a validated animal model of diabetes. Pharmacol Res 1996; 33:1–4.
80. Ojewole JA, Adewole SO, Olayiwola G. Hypoglycaemic and hypotensive effects of Momordica charantia
Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr 2006; 17:227–232.
81. Coon JT, Ernst E. Panax ginseng
: a systematic review of adverse effects and drug interactions. Drug Saf 2002; 25:323–344.
82. Quan HY, Yuan HD, Jung MS, Ko SK, Park YG, Chung SH. Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Int J Mol Med 2012; 29:73–80.
83. Shishtar E, Jovanovski E, Jenkins A, Vuksan V. Effects of Korean white ginseng (Panax ginseng
C.A. Meyer) on vascular and glycemic health in type 2 diabetes: results of a randomized, double blind, placebo-controlled, multiple-crossover, acute dose escalation trial. Clin Nutr Res 2014; 3:89–97.
84. Oh MR, Park SH, Kim SY, Back HI, Kim MG, Jeon JY, et al. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med 2014; 14:237.
85. Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, di Buono M, et al. Korean red ginseng (Panax ginseng
) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis 2008; 18:46–56.
86. Kim S, Shin BC, Lee MS, Lee H, Ernst E. Red ginseng for type 2 diabetes mellitus: a systematic review of randomized controlled trials. Chin J Integr Med 2011; 17:937–944.
87. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother 2006; 40:83–95.
88. Komishon AM, Shishtar E, Ha V, Sievenpiper JL, de Souza RJ, Jovanovski E, et al. The effect of ginseng (genus Panax
) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. J Hum Hypertens 2016; 30:619–626.
89. Salimifar M, Fatehi-Hassanabad Z, Fatehi M. A review on natural products for controlling type 2 diabetes with an emphasis on their mechanisms of actions. Curr Diabetes Rev 2013; 9:402–411.
90. Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18:1104–1112.
91. Duvall WL. Endothelial dysfunction and antioxidants. Mt Sinai J Med 2005; 72:71–80.
92. Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 2003; 8:169–175.
93. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2003; 285:H2392–H2398.
94. Tousoulis D, Antoniades C, Vasiliadou C, Kourtellaris P, Koniari K, Marinou K, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart 2007; 93:244–246.
95. Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabet Med 1999; 16:304–311.
96. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37–46.